Last reviewed · How we verify
Vaxzevria Vaccine — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Vaxzevria Vaccine (Vaxzevria Vaccine) — Clover Biopharmaceuticals AUS Pty. Vaxzevria Vaccine works by stimulating the body's immune system to produce a specific response against the SARS-CoV-2 virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vaxzevria Vaccine TARGET | Vaxzevria Vaccine | Clover Biopharmaceuticals AUS Pty | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vaxzevria Vaccine CI watch — RSS
- Vaxzevria Vaccine CI watch — Atom
- Vaxzevria Vaccine CI watch — JSON
- Vaxzevria Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Vaxzevria Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/vaxzevria-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab